WO2017182989A1 - Medication kit adapted to treat lesions of the integumentary tissues - Google Patents
Medication kit adapted to treat lesions of the integumentary tissues Download PDFInfo
- Publication number
- WO2017182989A1 WO2017182989A1 PCT/IB2017/052295 IB2017052295W WO2017182989A1 WO 2017182989 A1 WO2017182989 A1 WO 2017182989A1 IB 2017052295 W IB2017052295 W IB 2017052295W WO 2017182989 A1 WO2017182989 A1 WO 2017182989A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modules
- medication kit
- medication
- module
- container
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 229940079593 drug Drugs 0.000 title claims abstract description 59
- 230000003902 lesion Effects 0.000 title claims abstract description 41
- 210000001519 tissue Anatomy 0.000 claims abstract description 37
- 239000000835 fiber Substances 0.000 claims abstract description 27
- 239000000463 material Substances 0.000 claims abstract description 26
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 229920001436 collagen Polymers 0.000 claims abstract description 25
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 19
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 19
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 19
- 108010081750 Reticulin Proteins 0.000 claims abstract description 12
- 230000000295 complement effect Effects 0.000 claims abstract description 10
- 239000000560 biocompatible material Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 229960005274 benzocaine Drugs 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 240000000982 Malva neglecta Species 0.000 claims description 2
- 235000000060 Malva neglecta Nutrition 0.000 claims description 2
- 244000151637 Sambucus canadensis Species 0.000 claims description 2
- 235000018735 Sambucus canadensis Nutrition 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 2
- 240000002657 Thymus vulgaris Species 0.000 claims description 2
- 229920006125 amorphous polymer Polymers 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 235000007123 blue elder Nutrition 0.000 claims description 2
- 229910021538 borax Inorganic materials 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 2
- 229940046413 calcium iodide Drugs 0.000 claims description 2
- 229910001640 calcium iodide Inorganic materials 0.000 claims description 2
- 229920001971 elastomer Polymers 0.000 claims description 2
- 235000007124 elderberry Nutrition 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- 235000008995 european elder Nutrition 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 239000005060 rubber Substances 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001585 thymus vulgaris Substances 0.000 claims description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 claims 1
- 229940048910 thiosulfate Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 26
- 230000035876 healing Effects 0.000 description 18
- 238000002483 medication Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 12
- 210000004207 dermis Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000003592 biomimetic effect Effects 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 102000001187 Collagen Type III Human genes 0.000 description 6
- 108010069502 Collagen Type III Proteins 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000002861 polymer material Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001724 microfibril Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 206010006797 Burns first degree Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 102000013373 fibrillar collagen Human genes 0.000 description 2
- 108060002894 fibrillar collagen Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000030275 Chondronectin Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- -1 alginic acid salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012213 gelatinous substance Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000043667 human chondronectin Human genes 0.000 description 1
- 108700020610 human chondronectin Proteins 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F17/00—First-aid kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
- A61F13/01029—Non-adhesive bandages or dressings characterised by the structure of the dressing made of multiple layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00246—Wound bandages in a special way pervious to air or vapours
- A61F2013/00255—Wound bandages in a special way pervious to air or vapours with pores
Definitions
- the present invention refers to the medical field. More in detail, the present invention refers to a medication kit for use in the treatment of the lesions of the integumentary tissues caused by burns. Said kit is characterized in that it comprises medications which direct the lesion healing process in a biomimetic manner, limiting the aesthetic damage caused by the lesion as much as possible.
- burns are generally caused by the exposure of the tissue itself to heat sources, chemical substances, electrical sources or radiations.
- the burns that only affect the first skin layer are defined surface burns or first degree burns; when the damage penetrates into some of the underlying layers, the lesion is termed partial thickness burn or second degree burn; if instead the alteration involves all the skin layers, it is classified as a full thickness burn or third degree burn.
- a fourth degree burn involves lesions of the deepest tissues such as muscles and bone.
- the required treatment of course varies as a function of the type of burn, hence as a function of the gravity of the lesion: special alterations can be managed with simple analgesics, while large burns require a prolonged treatment in specialized centers.
- the partial thickness burns are diffusely treated by previously executing a cleaning with water and soap, followed by a medication. Burns over the entire thickness usually require surgical treatments, like skin grafts. Extensive burns often require the administration of large quantities of liquids intravenously, since the successive inflammatory response involves a formation of edema and significant losses of capillary fluid.
- treatment protocols more specifically provide for treating very slight burns (hence first degree burns) with suitable over-the-counter ointments, generally with benzocaine base.
- first degree burns very slight burns
- second degree burns where small blisters are usually encountered - which are not to be removed or punctured - if these are spontaneously opened
- the wounds are to be treated by using suitable gauzes containing antibiotic principles, after which one proceeds with the bandaging without compressing the wounds.
- the obtainment of a good aesthetic result depends not only on the type of damage to the tissues, but also on the medications employed during the healing treatments, which as desired must allow the cellular regeneration of the burn-affected parts, preventing the risk of contracting infections and ensuring that the new cellular growth of the tissues occurs in a manner such to reproduce the layers so that they are as similar as possible to those existing before the damage.
- This condition often depends on the accuracy with which the medications are executed on the patient, and of course on the medication type itself provided by the operators of the field in the aforesaid specialized centers and elsewhere.
- a treatment is in fact effective for such purpose if it is able to prevent infection, maintain the skin hydrated in order to facilitate the removal of the lesioned tissue, and if it is able to facilitate the regeneration of the tissues in a uniform manner.
- a recent solution to the problem of the lack of medications which avert aesthetic damage provides for the use of an innovative hydrogel formed by peptides capable of being self- assembled. More in detail, these are oligomeric peptides capable of being assembled in macromolecular nanofiber meshes. Such meshes, having an amphiphilic behavior, are able to trap a considerable quantity of water, up to 99.9%, thus forming a hydrogel that resembles the extracellular matrix.
- This hydrogel-based structure therefore depends on structural support for the new growth of the cells of the body in a biomimetic manner, and simultaneously acts as barrier against infections.
- the object of the present invention is to overcome the aforesaid critical issues by proposing a kit comprising medications having a surface structure, to be affixed on the burned surfaces, which itself represents a valid mechanical support for facilitating the new tissue growth in a biomimetic manner.
- the surfaces of the aforesaid medications are for such purpose structured so as to mimic the microstructure of the extracellular tissue matrix in its various depth levels.
- the kit comprises medications which preferably already comprise, in their structure, the substance/medicine to be administered to the patient.
- the native cellular matrix As is known, the latter appears as a gelatinous substance comprising a fibrous portion, composed of proteins, included in an aqueous solution of proteins, glycoproteins and proteoglycans.
- the proteins in question are: collagen, elastin, laminin, fibronectin, chondronectin and osteonectin.
- the extracellular matrix can be divided into: a matrix of amorphous material termed fundamental substance and a fibrillar component. Fibers of the connective tissue are immersed within the amorphous matrix and confer structural stability to the matrix.
- Such connective tissue fibers immersed in the amorphous substance are separated into three basic types, in accordance with their composition and structure: collagen fibers, reticular fibers and elastic fibers.
- collagen fibers are the fiber type most represented by the human organism and in the connective tissues; on their own, they represent the most abundant non-mineral component after water, constituting up to 6% of the body weight. They appear as long undulated fibers that are branched in two directions (e.g. in the case of loose connective tissue) or in multiple directions (e.g. in the case of regular dense connective tissue), they have a thickness that can vary from 1 to 12 ⁇ .
- Each collagen fiber is constituted by dozens of more slender fibrils, with 0.2-0.3 ⁇ diameter, which determine a longitudinal striation, immersed in an amorphous substance.
- Each collagen fibril is in turn constituted by micro-fibrils which are longitudinally associated with each other, determining the birefringence thereof.
- the micro-fibrils examined under the electron microscope, appear striated transverse to their larger axis; in particular the striations are repeated every 70 nm when wet or every 64 nm when dry, hence they have an axile periodicity of 64-70 nm.
- Collagen fibers are very resistant to traction, flexible but practically inextensible.
- fibrillar collagen constitutes 90% of the collagen in the body, constituting the bones, tendons, collagen fibers of the dermis and the dentin.
- Type II collagen is diffused in the cartilage and in the vitreous humor.
- Type III collagen is diffused in the dermis, in the muscles and in the wall of the blood vessels.
- Type IV collagen is diffused in the basal membranes.
- the reticular fibers constituted by type III collagen chains, are diffused in the loose connective tissue, in the muscles, in the endoneurium, in the adipose tissue, in the lymphoid organs and in the walls of the blood vessels. They are also constituted by fibrils and micro- fibrils that have axile periodicity of 64-70 nm, but the fibrils are more slender (average thickness of 50 nm) and consequently also the reticular fibers (variable thickness 0.5-2 ⁇ ) are more slender.
- the reticular fibers are not associated with each to form bundles, but rather constitute thin meshes or weaves, running over two levels or in three-dimensional sense, with wide spaces between the meshes occupying the amorphous matrix.
- the amorphous substance constitutes a compact gel in which the fibers are immersed. It is essentially constituted by macromolecules of carbohydrate origin termed glycosaminoglycans and from associations of the latter with proteins.
- the object of the present invention is therefore to provide a medication to be applied on the body portions damaged by burns which allows tissue regeneration so as to reproduce the native structure of the dermis, thus optimizing the aesthetic result.
- the medications of the kit are supports having a surface on which the incisions are present, defining a profile similar to the complementary profile of the above-described extracellular matrix.
- the object is therefore to ensure that the healing process occurs due both to the pharmaceutical composition and to its mechanical support that "directs" the cells of the dermis to grow to as to reproduce a macroscopic structure that is as similar as possible to that existing before the damage.
- the object of the present invention is to provide new structural supports shaped as scaffolds that allow guiding the cellular growth and reorganization.
- the modules of the kit are characterized in that they have particular incisures that increase the effectiveness of the scaffold.
- the present description refers to a medication kit for use in the treatment of the lesions of the integumentary tissues and in particular for use in the treatment of burns. Still more in detail the present description refers to a medication kit comprising a plurality of modular and modulatable structures made of specific breathable polymer materials having at least one surface with a micro structure which recalls that of the fundamental (amorphous) substance of the native extracellular matrix. More in detail, the present kit appears as a container shaped as a case in which a plurality of modular and modulatable elements are present, having the profile of anatomic and ergonomic human integumentary portions.
- each modular element is represented by a structure made of a biocompatible polymer material or chemically inert and breathable material, which has at least one surface having a microstructure similar to that of the native extracellular matrix present in the dermis.
- the present medication kit is in particular characterized in that each modular element has the profile of anatomic portions of the human integuments and at least one surface has an amorphous structure, similar to the amorphous substance of the native extracellular matrix, on which the grooves/incisures are present having a profile complementary to that of the collagen fibers and of the reticular fibers of the extracellular matrix, where by collagen fibers preferably the type III collagen fibers present in the dermis are intended.
- each of the aforesaid modular elements comprises, on said particular surface, a thickness of one of the pharmaceutical compositions conventionally used for healing lesions of the integumentary tissues caused by burns.
- the materials usable for making said modular structures are, by way of a non- limiting example, degradable polymer materials that lose their structural integrity with dynamics that vary from several weeks to several years in accordance with the interaction between their chemical structure and the environment that hosts them.
- PLA, PGA and PLGA are employed, i.e. alpha-hydroxy esters, or polyesters obtained from the polymerization of alpha-hydroxy acids.
- These are biocompatible and biodegradable compounds whose degradation products (such degradation occurring via non-enzymatic hydrolysis of the ester bonds in a physiological environment) are compounds with low molecular weight such as: lactic acid and glycolic acid, which enter into the normal metabolic paths, in fact they are normally expelled from the organism in the form of carbon dioxide and water.
- PLGA has a wide range of degradation speeds, from days to years in accordance with the ratio of the two monomers and/or of the molecular weight.
- several polymers of biological origin are to be included, such as alginates, chitosan, hyaluronic acid and collagen.
- the alginates, alginic acid salts are block copolymers composed of two monosaccharide units: L-guluronic acid and D-mannuronic acid (the regions constituted by blocks of the first acid form hydrogels in aqueous solutions of bivalent cations at room temperature; this characteristic is generally exploited for encapsulating drugs).
- Chitosan is a polysaccharide derived from chitin and consists of a monometric unit constituted by a relatively simple glucosamine. It is biocompatible and biodegradable.
- Hyaluronic acid is a linear polysaccharide composed of repeating units of glucoronic acid and N-acetyl glucosamine. By means of an esterification reaction, one can obtain a semi- synthetic biopolymer with different chemical-physical properties, without however altering the structure thereof.
- Collagen a natural component of the extracellular matrix of many connective tissues, and already widely used as support for the adhesion of tissues, facilitates the adhesion, proliferation and cellular metabolism.
- the present invention consists of a medication kit made, by way of a non-limiting example, with such aforesaid materials, which is characterized in that each of said medications has at least one surface made with such materials but not limited to said materials, on which incisures are present with profile complementary to that of the fibers present in the native human extracellular matrix.
- the size of such incisures is complementary and mirrored with respect to that of the type III collagen fibers and of the reticular fibers present in the dermis.
- Such medications indicated herein as modules, are therefore innovative scaffolds which are proposed for promoting the organization of the new cellular growth of the lesioned integumentary portion in a more efficient manner with respect to the conventional scaffolds.
- each module has the profile of anatomic portions of the human integuments and comprises, on the surface to be affixed on the lesioned zone, a thickness of a drug, typically in ointment form, conventionally used for healing wounds.
- the present medication kit is proposed for acting as an instrument that is easy to use and with a consistent effectiveness in the treatment of burns, aiming for the obtainment of an optimal aesthetic result at the end of the treatment. More in detail, the kit allows healing wounds with conventional drugs and executes a fine adjustment in the process of structural growth organization. All this while avoiding the use of sophisticated and costly processes for encapsulating drugs, growth factors and/or cells.
- the present medication kit due to the action of the drug previously spread on the surface of the module to be affixed on the lesion, effectively induces the healing process, preventing the risk of infection onset, and due to the microstructure of the surface below the drug layer it allows executing a fine adjustment of the cellular reorganization in a biomimetic manner.
- said medications of the kit in primis allow effectively treating the lesions and subsequently allow making possible the obtainment of an optimal aesthetic result at the end of the treatment, due to the innovative scaffold below the layer of drug that acted.
- the modules representing the medications of the present kit are made with materials that preferably have properties such as: biocompatibility, hence non-toxicity together with the capacity to interact with the immune response of the organism, facilitating tissue cell growth and development mechanisms; ability to be biodegradable and/or bioresorbable, for which it should be considered that the time of degradation of the materials constituting the scaffolding must be strictly coordinated with that of the formation of the new tissue so that the overly quick degradation of the matrix does not allow the formation of a complete and strong tissue, while overly long times induce the formation of tissue around the scaffold in an imperfect or incomplete manner.
- the scaffolds of the present kit and hence the modules of said kit preferably have dimensions of the surfaces of the pores comprised between 20 and 150 ⁇ .
- the materials of the modules of the kit can also be easily processed, allowing the manufacturing thereof reproducible on an industrial scale, and they can also be sterilized without there being processes of degradation.
- the techniques used for making the materials of said modules of the kit are known techniques such as: fiber bonding; electro spinning; microsphere sintering; solvent casting-particulate leaching; phase separation; solid freeform and others.
- an instrument in order to obtain the particular micro structure and nanostructure of the surfaces, i.e. in order to obtain incisures with profile similar to the complementary profile of the fibers of the extracellular matrix of the dermis, an instrument can be used that is provided with a movable micrometer and nanometer needle.
- FIGURE 1 shows an exemplifying view of some of the components of the medication kit for the treatment of the lesions of the integumentary tissues, object of the present industrial invention patent application.
- the figure in question shows the profile of several of the modules 20 comprised in said kit.
- the figure intends to show in particular that each module 20, structured shaped as flexible flap, has a profile shaped as anatomic portions of the human integuments.
- the figure in question shows modules 20 with profile similar to that of integumentary portions of the face, of the thoracic back, of a limb such as a forearm, a thumb or an abdomen.
- FIGURE 2 shows an exemplifying representation of the surface 20' characterizing each module 20 of the present medication kit. More in detail, the figure in question intends to show that said kit is characterized in that each of the modules 20 comprised therein has a surface 20' having a plurality of incisures (fig. 2(a)). In particular: first longitudinal incisures 20", second longitudinal microincisures 20"' defining a system of striated longitudinal bands; and third incisures 20"" oriented shaped as thin meshes and weaves.
- each module 20 The goal of such structure of the surface 20' of each module 20 is to define a scaffold with guide incisures that are, both respect to size and space, as complementary as possible to the type III collagen fibers and reticular fibers of the native extracellular matrix. All this in order to facilitate the process of healing the lesion in a biomimetic manner.
- Figure 2(b) instead shows a front view of a portion of the thickness of a module 20. More in detail the figure in question intends to show that on the surface 20' of the module 20, a film 30 is present of variable thickness of a common medicine adapted for the treatment of lesions of the integumentary tissues caused by burns.
- FIGURE 3 shows an exemplifying perspective view of the container 10 shaped as case adapted for containing the modules 20 of the present kit. More in detail, the figure in question shows that said container 10 comprises a plurality of compartments, each adapted for containing at least one module 20.
- the figure under examination also refers to a particular embodiment in which said container 10 shaped as case comprises a sterile scalpel 40 and a layer of flexible and chemically inert material shaped as mat 50 adapted to offer abutment to said modules 20, if it is of interest to further modulate said modules with the aid of the scalpel 40 in order to render them as adaptable and extensible as possible on the surface of the human integument affected by the lesion.
- the medication kit for the treatment of lesions on the integumentary tissues comprises a box-like container 10 or case and a plurality of modules 20 shaped as flexible flaps to be affixed on the lesion to be treated. More in detail, said kit comprises a plurality of modules made of materials chemically inert with the human integumentary tissues, or of biocompatible materials and/or bioresorbable materials. By way of a non-limiting example, said materials are represented by: alpha-hydroxy esters, i.e.
- each of said modules 20 shaped as flexible flaps has, on at least one of the surfaces and in particular on the surface 20' to be affixed on the anatomic portion affected by the lesion, a structure having a plurality of incisures 20" having a profile dimensionally complementary to that of the collagen fibers and of the reticular fibers of the extracellular matrix, and in particular dimensionally complementary to the type III collagen fibers.
- both the orientation/distribution of said incisures 20' on said surface 20' and their size are as mirrored as possible with respect to that of the aforesaid native fibers.
- the technical effect deriving from such characteristic is to promote a tissue regeneration in a biomimetic manner, with an even finer adjustment than that associated with known scaffolds.
- the medication kit for lesions of the integumentary tissues comprises a plurality of modules 20, each having a surface 20' on which first longitudinal incisures 20" are present with a width of their transverse section comprised between 1 and 12 ⁇ .
- second longitudinal microincisures 20"' are present having a width of the transverse sections comprised between 0.2-0.3 ⁇ .
- Said first longitudinal incisures 20" and second longitudinal microincisures 20"' define a system of striated longitudinal bands.
- said second microincisures 20"' are repeated on each of the surfaces 20' of each module 20 with an axile periodicity of 64-70 nm.
- third incisures 20"" are also present, shaped as thin meshes and weaves. In order to render each module breathable, each of these has pores having a surface area comprised between 20-150 ⁇ .
- each of said modules 20 has a film adsorbed on the surface 20' thereof; such film of variable thickness is a common medicine adapted to treat lesions represented by burns.
- said medicine is in the form of an oil/unguent or ointment or foam.
- a film 30 of an ointment is present with the following composition:
- the film 30 of said medicine is also preferably covered with a film of chemically inert material that is if necessary removed.
- the present medication kit comprises a plurality of modules 20 which have, as stated above, the profile of anatomic portions of the human integuments.
- modules 20 which have, as stated above, the profile of anatomic portions of the human integuments.
- each of said modules 20 is further modulatable in a manner so as to allow its adaptation to the lesioned portion as a function of the extension of the lesion, which can even be relatively small.
- said kit is preferably provided with at least one sterile scalpel 40 and with a layer of chemically inert and sterile material shaped as flexible mat 50 on which it is possible to extend the module 20 that one intends to cut in order to obtain a particular profile thereof, by means of the use of said sterile scalpel 40. If requested, such operation occurs by extending the module 20 on said sterile and flexible mat 50, in a manner so as to affix on the latter the surface opposite the surface 20' of the module 20. Subsequently, with the aid of the scalpel, the profile is defined which the module 20 must assume for its optimal adaptation on the lesion.
- the modules 20 of the kit can be arranged within the container 10 shaped as case, and provided with suitable compartments, also in bent shape.
- the fine adjustment of the lesion healing process aimed for obtaining a satisfactory aesthetic result, occurs as the final step of the healing process. Indeed it is assumed that the lesioned subject was first subjected to a prior curative treatment, in primis aimed to prevent the risk of infection by following standard first aid protocols.
- the medicinal film has essentially curative function, preferably to be performed however after the actuation of a previous standard protocol for the treatment of the burns, so that the possible bent shape of the module does not comprise the outcome of the treatment.
- the latter is in fact related to the aforesaid structure of the surface 20' of each module, on which the medicine is adsorbed in a manner so as to penetrate said incisures, ensuring that the final step of the healing process occurs in a biomimetic manner.
- the medication kit preferably comprises a container 10 shaped as a refrigerator case.
- each compartment has at least one indication such as a label or the like indicating the module 20 type, with the profile of specific anatomic portions of the human integuments contained in the compartment(s).
- said modules 20 can have indications such as writing, numbers or figures adapted for the recognition thereof, and the container 10 can also comprise an illustrative key or sheet that illustrates how to identify and use said modules 20 and in general the present kit.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Medication kit, said medication kit comprising a box-like container (10) or case and a plurality of modules (20) shaped as flexible flaps to be affixed on the lesion to be treated, said modules (20) being shaped as anatomic portions of the human integuments and being contained in suitable compartments present in said container (10), said modules (20) being made of materials chemically inert with the human integumentary tissues, or of biocompatible materials and/or bioresorbable materials, said kit being characterized in that each of said modules (20) shaped as flexible flaps has, on at least one of its surfaces, a plurality of incisures having a profile dimensionally complementary and mirrored with respect to that of the collagen fibers and of the reticular fibers of the native extracellular matrix.
Description
"Medication kit adapted to treat lesions of the integumentary tissues"
Description Field of the art
The present invention refers to the medical field. More in detail, the present invention refers to a medication kit for use in the treatment of the lesions of the integumentary tissues caused by burns. Said kit is characterized in that it comprises medications which direct the lesion healing process in a biomimetic manner, limiting the aesthetic damage caused by the lesion as much as possible.
State of the art
The problem relative to the treatment of body lesions, commonly known as burns, caused by heat sources of various nature has been felt since ancient times. Recent findings have also shown that most of the recurring episodes increasingly take place at home, especially involving children and elderly people. The causes of such accidents can often be traced to the poor handling skills of potentially dangerous home objects, and to the ignorance and/or superficial nature of evaluation of the potential burn-causing risk associated with various types of objects of daily use. Hence, if on one hand in recent decades there has been a progressive decrease of accidents encounterable at the workplace due to the increase of adopted safety measures, on the other hand there has been an increase of this accident type in the home, which as stated above mainly involves the elderly and children.
Presently, the treatments for these types of lesions of the integumentary tissues are constantly evolving, with the goal of repairing the damage as much as possible and significantly optimizing the prognosis.
As is known, burns are generally caused by the exposure of the tissue itself to heat sources, chemical substances, electrical sources or radiations. The burns that only affect the first skin layer are defined surface burns or first degree burns; when the damage penetrates into some
of the underlying layers, the lesion is termed partial thickness burn or second degree burn; if instead the alteration involves all the skin layers, it is classified as a full thickness burn or third degree burn. A fourth degree burn involves lesions of the deepest tissues such as muscles and bone. The required treatment of course varies as a function of the type of burn, hence as a function of the gravity of the lesion: special alterations can be managed with simple analgesics, while large burns require a prolonged treatment in specialized centers. Usually, the partial thickness burns are diffusely treated by previously executing a cleaning with water and soap, followed by a medication. Burns over the entire thickness usually require surgical treatments, like skin grafts. Extensive burns often require the administration of large quantities of liquids intravenously, since the successive inflammatory response involves a formation of edema and significant losses of capillary fluid.
The most common complications and consequences correlated to burns are tied to infections: immunodepression is always present and underlies the problems of infective type, which occur to the detriment of the burn-affected zones. One then enters into the chronic phase characterized by a considerable reduction of body weight, due to an acceleration of the metabolism, and by hypoproteinemia which can cause functional deficiencies at several vital organs.
Presently, treatment protocols more specifically provide for treating very slight burns (hence first degree burns) with suitable over-the-counter ointments, generally with benzocaine base. In the case of second degree burns, meanwhile, where small blisters are usually encountered - which are not to be removed or punctured - if these are spontaneously opened, the wounds are to be treated by using suitable gauzes containing antibiotic principles, after which one proceeds with the bandaging without compressing the wounds.
In case of more severe burns (third and fourth degree burns), the subject must be admitted as soon as possible in a hospital equipped for emergencies of this type and undergo all the specific treatments for this burn type.
Much statistical data shows that about 95% of burns can be treated at the outpatient level. The objectives of all the treatments comprise a quick healing of the lesions, control of the
pain, recovery of the normal functions of the burnt area and a good aesthetic outcome. The latter is undoubtedly one of the desired objectives to be attained, once the risk of compromising burn area functionality has been averted. For such purpose, it is to be considered that in many cases the obtainment of a good aesthetic result depends not only on the type of damage to the tissues, but also on the medications employed during the healing treatments, which as desired must allow the cellular regeneration of the burn-affected parts, preventing the risk of contracting infections and ensuring that the new cellular growth of the tissues occurs in a manner such to reproduce the layers so that they are as similar as possible to those existing before the damage. This condition often depends on the accuracy with which the medications are executed on the patient, and of course on the medication type itself provided by the operators of the field in the aforesaid specialized centers and elsewhere.
However, today experts widely recognize the actual existence of an unsatisfied clinical need for medications for the treatment of all those burns that can create serious skin damage. A treatment is in fact effective for such purpose if it is able to prevent infection, maintain the skin hydrated in order to facilitate the removal of the lesioned tissue, and if it is able to facilitate the regeneration of the tissues in a uniform manner.
It is also indicated that when the lesion is deeper, even touching the dermis below where the stem cells are found, the capacity of the latter cells to regenerate the tissue is also compromised. Consequently, an emergency system is activated which draws stem cells from the adjacent cells, thus involving a considerable increase of the healing time required, as well as the increase of the risk of contracting infections. Even if many deep lesion treatments, in particular the treatment of full thickness lesions, provide for skin grafts for activating the tissue regeneration, it is hard to find effective and accurate medications for the partial thickness lesions. The protocols for this wound type provide for the application of a silver- based antibiotic in order to prevent infection, and they provide for coverage with silicone medications which do not compromise the regeneration of the epidermis during the medication changes. Nevertheless, such material, depending on its thickness, does not
always ensure cellular respiration, rendering the hydration process very slow, such process being essential for creating the lesioned tissue layer to be removed.
A recent solution to the problem of the lack of medications which avert aesthetic damage provides for the use of an innovative hydrogel formed by peptides capable of being self- assembled. More in detail, these are oligomeric peptides capable of being assembled in macromolecular nanofiber meshes. Such meshes, having an amphiphilic behavior, are able to trap a considerable quantity of water, up to 99.9%, thus forming a hydrogel that resembles the extracellular matrix. This hydrogel-based structure therefore depends on structural support for the new growth of the cells of the body in a biomimetic manner, and simultaneously acts as barrier against infections.
Other presently known solutions provide for the use of tissue engineering for healing the wounds and regenerating the tissues. The obtainment of such products derives from the awareness of the importance that the extracellular matrix assumes in the processes of cellular regeneration and healing. In particular, the recognition of the importance that the extracellular matrix assumes in the healing processes has led to the development of products such to stimulate or substitute the damaged extracellular matrix.
Among these products of tissue engineering, synthetic or natural collagen matrices are known which mimic the structural and functional characteristics of the native extracellular matrix. Such matrix-like tissues, once introduced in the lesion, provide a temporary scaffolding or support onto which the cells can migrate and proliferate in an organized manner, leading to the regeneration of the lesioned body tissue and finally to the healing of the wound. Such products can be either cellular (hence containing live cells) or acellular (biologically insert) and be of natural or synthetic origin or mixed. Presently, these matrices have use above all in the healing of lesions that are hard to cicatrize, such as venous ulcers of the leg. Even if the use of tissue engineering products always fall within the field of sophisticated and advanced methods for managing complex wounds, the potential disadvantages associated with the use of such materials are the risk of transfer of infective agents and immune reaction. In addition, the processes of production, transport, preservation
etc. of these products are quite expensive, consequently involving a limited clinical use. It must also be considered, as stated above, that in the case of body lesions such as burns there are no valid medications and/or instruments which allow applying the medicating substances adapted to prevent infection and facilitate the tissue regeneration in a uniform manner, increasingly seeking to optimize the aesthetic result at the end of the treatment.
For such purpose, the object of the present invention, described in detail hereinbelow, is to overcome the aforesaid critical issues by proposing a kit comprising medications having a surface structure, to be affixed on the burned surfaces, which itself represents a valid mechanical support for facilitating the new tissue growth in a biomimetic manner. The surfaces of the aforesaid medications are for such purpose structured so as to mimic the microstructure of the extracellular tissue matrix in its various depth levels. In such a manner, also the substances conventionally used for the treatment and care of burns can be used. More in detail the kit comprises medications which preferably already comprise, in their structure, the substance/medicine to be administered to the patient.
For the purpose of comprehension of the present industrial invention patent application, it is of interest to report a brief description of the native cellular matrix. As is known, the latter appears as a gelatinous substance comprising a fibrous portion, composed of proteins, included in an aqueous solution of proteins, glycoproteins and proteoglycans. The proteins in question are: collagen, elastin, laminin, fibronectin, chondronectin and osteonectin. More in detail, the extracellular matrix can be divided into: a matrix of amorphous material termed fundamental substance and a fibrillar component. Fibers of the connective tissue are immersed within the amorphous matrix and confer structural stability to the matrix. Such connective tissue fibers immersed in the amorphous substance are separated into three basic types, in accordance with their composition and structure: collagen fibers, reticular fibers and elastic fibers. For the comprehension of the present invention, the collagen fibers and the reticular fibers are of particular interest. Collagen fibers are the fiber type most represented by the human organism and in the connective tissues; on their own, they represent the most abundant non-mineral component after water, constituting up to 6% of the body weight.
They appear as long undulated fibers that are branched in two directions (e.g. in the case of loose connective tissue) or in multiple directions (e.g. in the case of regular dense connective tissue), they have a thickness that can vary from 1 to 12 μηι. Each collagen fiber is constituted by dozens of more slender fibrils, with 0.2-0.3 μηι diameter, which determine a longitudinal striation, immersed in an amorphous substance. Each collagen fibril is in turn constituted by micro-fibrils which are longitudinally associated with each other, determining the birefringence thereof. The micro-fibrils, examined under the electron microscope, appear striated transverse to their larger axis; in particular the striations are repeated every 70 nm when wet or every 64 nm when dry, hence they have an axile periodicity of 64-70 nm. Collagen fibers are very resistant to traction, flexible but practically inextensible. The various types of collagen, 29, can be divided into three classes: fibrillar collagen, collagen associated with fibrils and laminar or reticular collagen. Of interest for the following description is the fibrillar collagen class: these are the most common collagen fibers, on their own they constitute nearly all of the collagen of the human body, and collagen of type I, II, III, IV belong thereto. Type I collagen constitutes 90% of the collagen in the body, constituting the bones, tendons, collagen fibers of the dermis and the dentin. Type II collagen is diffused in the cartilage and in the vitreous humor. Type III collagen is diffused in the dermis, in the muscles and in the wall of the blood vessels. Type IV collagen is diffused in the basal membranes.
The reticular fibers, constituted by type III collagen chains, are diffused in the loose connective tissue, in the muscles, in the endoneurium, in the adipose tissue, in the lymphoid organs and in the walls of the blood vessels. They are also constituted by fibrils and micro- fibrils that have axile periodicity of 64-70 nm, but the fibrils are more slender (average thickness of 50 nm) and consequently also the reticular fibers (variable thickness 0.5-2 μηι) are more slender. The reticular fibers are not associated with each to form bundles, but rather constitute thin meshes or weaves, running over two levels or in three-dimensional sense, with wide spaces between the meshes occupying the amorphous matrix. They do not have the longitudinal striation of the collagen fibers.
The amorphous substance constitutes a compact gel in which the fibers are immersed. It is essentially constituted by macromolecules of carbohydrate origin termed glycosaminoglycans and from associations of the latter with proteins.
The object of the present invention is therefore to provide a medication to be applied on the body portions damaged by burns which allows tissue regeneration so as to reproduce the native structure of the dermis, thus optimizing the aesthetic result. More in detail, the medications of the kit are supports having a surface on which the incisions are present, defining a profile similar to the complementary profile of the above-described extracellular matrix. On such surface, preferably known curative compositions are extended for the treatment of the burns of the integumentary tissues. More clearly, the object is therefore to ensure that the healing process occurs due both to the pharmaceutical composition and to its mechanical support that "directs" the cells of the dermis to grow to as to reproduce a macroscopic structure that is as similar as possible to that existing before the damage. More in detail, the object of the present invention, described in detail hereinbelow, is to provide new structural supports shaped as scaffolds that allow guiding the cellular growth and reorganization. With respect to the known scaffolds, the modules of the kit are characterized in that they have particular incisures that increase the effectiveness of the scaffold.
Description of the invention
The present description refers to a medication kit for use in the treatment of the lesions of the integumentary tissues and in particular for use in the treatment of burns. Still more in detail the present description refers to a medication kit comprising a plurality of modular and modulatable structures made of specific breathable polymer materials having at least one surface with a micro structure which recalls that of the fundamental (amorphous) substance of the native extracellular matrix. More in detail, the present kit appears as a container shaped as a case in which a plurality of modular and modulatable elements are present, having the profile of anatomic and ergonomic human integumentary portions. Still more in detail, each modular element is represented by a structure made of a biocompatible polymer
material or chemically inert and breathable material, which has at least one surface having a microstructure similar to that of the native extracellular matrix present in the dermis. The present medication kit is in particular characterized in that each modular element has the profile of anatomic portions of the human integuments and at least one surface has an amorphous structure, similar to the amorphous substance of the native extracellular matrix, on which the grooves/incisures are present having a profile complementary to that of the collagen fibers and of the reticular fibers of the extracellular matrix, where by collagen fibers preferably the type III collagen fibers present in the dermis are intended. Even the spatial orientation of said grooves is similar and preferably mirrored with respect to that of the aforesaid collagen fibers and reticular fibers present in the native extracellular matrix present in the dermis. In addition, each of the aforesaid modular elements comprises, on said particular surface, a thickness of one of the pharmaceutical compositions conventionally used for healing lesions of the integumentary tissues caused by burns. Before entering into the discussion of the following description of the preferred embodiments, it should be indicated that the materials employed for making the modular structures of the kit are natural or synthetic polymer materials with specific chemical-physical characteristics and properties. More in detail, the materials usable for making said modular structures are, by way of a non- limiting example, degradable polymer materials that lose their structural integrity with dynamics that vary from several weeks to several years in accordance with the interaction between their chemical structure and the environment that hosts them. Preferably, PLA, PGA and PLGA are employed, i.e. alpha-hydroxy esters, or polyesters obtained from the polymerization of alpha-hydroxy acids. These are biocompatible and biodegradable compounds whose degradation products (such degradation occurring via non-enzymatic hydrolysis of the ester bonds in a physiological environment) are compounds with low molecular weight such as: lactic acid and glycolic acid, which enter into the normal metabolic paths, in fact they are normally expelled from the organism in the form of carbon dioxide and water. In addition, PLGA has a wide range of degradation speeds, from days to years in accordance with the ratio of the two monomers and/or of the molecular weight. In
addition, in the scope of bioresorbable polymer materials, several polymers of biological origin are to be included, such as alginates, chitosan, hyaluronic acid and collagen. More in detail, the alginates, alginic acid salts, are block copolymers composed of two monosaccharide units: L-guluronic acid and D-mannuronic acid (the regions constituted by blocks of the first acid form hydrogels in aqueous solutions of bivalent cations at room temperature; this characteristic is generally exploited for encapsulating drugs). Chitosan is a polysaccharide derived from chitin and consists of a monometric unit constituted by a relatively simple glucosamine. It is biocompatible and biodegradable. Hyaluronic acid is a linear polysaccharide composed of repeating units of glucoronic acid and N-acetyl glucosamine. By means of an esterification reaction, one can obtain a semi- synthetic biopolymer with different chemical-physical properties, without however altering the structure thereof. Collagen, a natural component of the extracellular matrix of many connective tissues, and already widely used as support for the adhesion of tissues, facilitates the adhesion, proliferation and cellular metabolism. As anticipated, the present invention consists of a medication kit made, by way of a non-limiting example, with such aforesaid materials, which is characterized in that each of said medications has at least one surface made with such materials but not limited to said materials, on which incisures are present with profile complementary to that of the fibers present in the native human extracellular matrix. In particular, the size of such incisures is complementary and mirrored with respect to that of the type III collagen fibers and of the reticular fibers present in the dermis. Such medications, indicated herein as modules, are therefore innovative scaffolds which are proposed for promoting the organization of the new cellular growth of the lesioned integumentary portion in a more efficient manner with respect to the conventional scaffolds. In addition, each module has the profile of anatomic portions of the human integuments and comprises, on the surface to be affixed on the lesioned zone, a thickness of a drug, typically in ointment form, conventionally used for healing wounds. Thus, the present medication kit is proposed for acting as an instrument that is easy to use and with a consistent effectiveness in the treatment of burns, aiming for the obtainment of an optimal aesthetic result at the end
of the treatment. More in detail, the kit allows healing wounds with conventional drugs and executes a fine adjustment in the process of structural growth organization. All this while avoiding the use of sophisticated and costly processes for encapsulating drugs, growth factors and/or cells. Still more in detail, the present medication kit, due to the action of the drug previously spread on the surface of the module to be affixed on the lesion, effectively induces the healing process, preventing the risk of infection onset, and due to the microstructure of the surface below the drug layer it allows executing a fine adjustment of the cellular reorganization in a biomimetic manner. Thus, said medications of the kit in primis allow effectively treating the lesions and subsequently allow making possible the obtainment of an optimal aesthetic result at the end of the treatment, due to the innovative scaffold below the layer of drug that acted. It is also of interest to indicate that the modules representing the medications of the present kit are made with materials that preferably have properties such as: biocompatibility, hence non-toxicity together with the capacity to interact with the immune response of the organism, facilitating tissue cell growth and development mechanisms; ability to be biodegradable and/or bioresorbable, for which it should be considered that the time of degradation of the materials constituting the scaffolding must be strictly coordinated with that of the formation of the new tissue so that the overly quick degradation of the matrix does not allow the formation of a complete and strong tissue, while overly long times induce the formation of tissue around the scaffold in an imperfect or incomplete manner. Particular importance was also given to the macrostructure and microstructure of the scaffolds with the intention of promoting the proliferation of the cells and the production of a matrix, specific for the cells, which should replace the role of the scaffold after the degradation of the latter. Also the porosity of the scaffolds was defined with the intention of allowing the diffusion of the nutrient substances and the elimination of the waste. In particular, the scaffolds of the present kit and hence the modules of said kit preferably have dimensions of the surfaces of the pores comprised between 20 and 150μιη. The materials of the modules of the kit can also be easily processed, allowing the manufacturing thereof reproducible on an industrial scale, and they can also be sterilized
without there being processes of degradation. The techniques used for making the materials of said modules of the kit are known techniques such as: fiber bonding; electro spinning; microsphere sintering; solvent casting-particulate leaching; phase separation; solid freeform and others.
In order to obtain the particular micro structure and nanostructure of the surfaces, i.e. in order to obtain incisures with profile similar to the complementary profile of the fibers of the extracellular matrix of the dermis, an instrument can be used that is provided with a movable micrometer and nanometer needle. Brief description of the drawings
FIGURE 1 shows an exemplifying view of some of the components of the medication kit for the treatment of the lesions of the integumentary tissues, object of the present industrial invention patent application.
More in detail, the figure in question shows the profile of several of the modules 20 comprised in said kit. The figure intends to show in particular that each module 20, structured shaped as flexible flap, has a profile shaped as anatomic portions of the human integuments. In particular, the figure in question shows modules 20 with profile similar to that of integumentary portions of the face, of the thoracic back, of a limb such as a forearm, a thumb or an abdomen.
FIGURE 2 shows an exemplifying representation of the surface 20' characterizing each module 20 of the present medication kit. More in detail, the figure in question intends to show that said kit is characterized in that each of the modules 20 comprised therein has a surface 20' having a plurality of incisures (fig. 2(a)). In particular: first longitudinal incisures 20", second longitudinal microincisures 20"' defining a system of striated longitudinal bands; and third incisures 20"" oriented shaped as thin meshes and weaves. The goal of such structure of the surface 20' of each module 20 is to define a scaffold with guide incisures that are, both respect to size and space, as complementary as possible to the type III collagen fibers and reticular fibers of the native extracellular matrix. All this in order to facilitate the
process of healing the lesion in a biomimetic manner. Figure 2(b) instead shows a front view of a portion of the thickness of a module 20. More in detail the figure in question intends to show that on the surface 20' of the module 20, a film 30 is present of variable thickness of a common medicine adapted for the treatment of lesions of the integumentary tissues caused by burns.
FIGURE 3 shows an exemplifying perspective view of the container 10 shaped as case adapted for containing the modules 20 of the present kit. More in detail, the figure in question shows that said container 10 comprises a plurality of compartments, each adapted for containing at least one module 20. The figure under examination also refers to a particular embodiment in which said container 10 shaped as case comprises a sterile scalpel 40 and a layer of flexible and chemically inert material shaped as mat 50 adapted to offer abutment to said modules 20, if it is of interest to further modulate said modules with the aid of the scalpel 40 in order to render them as adaptable and extensible as possible on the surface of the human integument affected by the lesion.
Description of the preferred embodiments
In all embodiments thereof, the medication kit for the treatment of lesions on the integumentary tissues, object of the present industrial invention patent application, comprises a box-like container 10 or case and a plurality of modules 20 shaped as flexible flaps to be affixed on the lesion to be treated. More in detail, said kit comprises a plurality of modules made of materials chemically inert with the human integumentary tissues, or of biocompatible materials and/or bioresorbable materials. By way of a non-limiting example, said materials are represented by: alpha-hydroxy esters, i.e. polyesters obtained from the polymerization of alpha-hydroxy acids such as PLA, PGA and PLGA, or block copolymers such as the aforesaid alginates, or more simply amorphous polymers such as EPR rubbers. As mentioned several times above, the present kit is substantially characterized in that each of said modules 20 shaped as flexible flaps has, on at least one of the surfaces and in particular on the surface 20' to be affixed on the anatomic portion affected by the lesion, a
structure having a plurality of incisures 20" having a profile dimensionally complementary to that of the collagen fibers and of the reticular fibers of the extracellular matrix, and in particular dimensionally complementary to the type III collagen fibers. More clearly, both the orientation/distribution of said incisures 20' on said surface 20' and their size are as mirrored as possible with respect to that of the aforesaid native fibers. The technical effect deriving from such characteristic is to promote a tissue regeneration in a biomimetic manner, with an even finer adjustment than that associated with known scaffolds.
In its preferred embodiment, the medication kit for lesions of the integumentary tissues comprises a plurality of modules 20, each having a surface 20' on which first longitudinal incisures 20" are present with a width of their transverse section comprised between 1 and 12 μηι. Preferably, within each of said first longitudinal incisures 20", second longitudinal microincisures 20"' are present having a width of the transverse sections comprised between 0.2-0.3 μηι. Said first longitudinal incisures 20" and second longitudinal microincisures 20"' define a system of striated longitudinal bands. In addition, said second microincisures 20"' are repeated on each of the surfaces 20' of each module 20 with an axile periodicity of 64-70 nm. On said surface 20' of each module 20, third incisures 20"" are also present, shaped as thin meshes and weaves. In order to render each module breathable, each of these has pores having a surface area comprised between 20-150 μιη .
As already mentioned, each of said modules 20 has a film adsorbed on the surface 20' thereof; such film of variable thickness is a common medicine adapted to treat lesions represented by burns. Preferably, said medicine is in the form of an oil/unguent or ointment or foam. By way of a non-limiting example, in one of its embodiments, on the surface 20' of each module 20, a film 30 of an ointment is present with the following composition:
8% to 10% of a decoction based on thyme, elderberry and mallow; 40% to 45% of soybean oil; 23% to 29% of hydrophilic emulsifying emollient with base of C12-C13 alcohol lactate and/or polyglycerols, 0.7% to 1.4% of benzocaine; 0.08% to 0.3% of colloidal sulfur; 2% to 6% of benzyl alcohol; 0.3% to 0.9% of sodium borate; 0.07% to 0.5% of calcium hydrate; 0.07% to 0.5% of calcium iodide; 0.05% to 0.4% of potassium iodide, 0.01% to 0.05% of
thiosulfate. The film 30 of said medicine is also preferably covered with a film of chemically inert material that is if necessary removed.
In all embodiments thereof, the present medication kit comprises a plurality of modules 20 which have, as stated above, the profile of anatomic portions of the human integuments. By way of a non-limiting example, shaped as the integumentary tissues of face portions, of limb portions, of thorax portions, etc. Nevertheless, in order to enhance the versatility of the present kit, each of said modules 20 is further modulatable in a manner so as to allow its adaptation to the lesioned portion as a function of the extension of the lesion, which can even be relatively small. For such purpose, said kit is preferably provided with at least one sterile scalpel 40 and with a layer of chemically inert and sterile material shaped as flexible mat 50 on which it is possible to extend the module 20 that one intends to cut in order to obtain a particular profile thereof, by means of the use of said sterile scalpel 40. If requested, such operation occurs by extending the module 20 on said sterile and flexible mat 50, in a manner so as to affix on the latter the surface opposite the surface 20' of the module 20. Subsequently, with the aid of the scalpel, the profile is defined which the module 20 must assume for its optimal adaptation on the lesion. Then, one proceeds with the removal of said film from the medicine layer adsorbed on the surface 20' and finally setting the module 20 and in particular said surface 20' on the lesion. The modules 20 of the kit can be arranged within the container 10 shaped as case, and provided with suitable compartments, also in bent shape. In fact, the fine adjustment of the lesion healing process, aimed for obtaining a satisfactory aesthetic result, occurs as the final step of the healing process. Indeed it is assumed that the lesioned subject was first subjected to a prior curative treatment, in primis aimed to prevent the risk of infection by following standard first aid protocols. The medicinal film has essentially curative function, preferably to be performed however after the actuation of a previous standard protocol for the treatment of the burns, so that the possible bent shape of the module does not comprise the outcome of the treatment. The latter is in fact related to the aforesaid structure of the surface 20' of each module, on which the medicine is adsorbed in a manner so as to penetrate said incisures, ensuring that the final
step of the healing process occurs in a biomimetic manner.
In all embodiments thereof, the medication kit preferably comprises a container 10 shaped as a refrigerator case. In addition, in order to facilitate the use in identifying modules 20 of interest, each compartment has at least one indication such as a label or the like indicating the module 20 type, with the profile of specific anatomic portions of the human integuments contained in the compartment(s). For the same purpose, also said modules 20 can have indications such as writing, numbers or figures adapted for the recognition thereof, and the container 10 can also comprise an illustrative key or sheet that illustrates how to identify and use said modules 20 and in general the present kit.
Claims
Medication kit, said medication kit comprising a box-like container (10) or case and a plurality of modules (20) shaped as flexible flaps to be affixed on the lesion to be treated, said modules (20) being shaped as anatomic portions of the human integuments and being contained in suitable compartments present in said container (10), said modules (20) being made of materials chemically inert with the human integumentary tissues, or made of biocompatible materials and/or of bioresorbable materials, said kit being characterized in that each of said flexible flap-like modules (20) has, on at least one of its surfaces, a plurality of incisures having a profile dimensionally complementary and mirrored with respect to that of the collagen fibers and of the reticular fibers of the native extracellular matrix, each of said modules (20) having - on its surface (20') to be affixed on the lesion to be treated - first longitudinal incisures (20") having a width of their transverse section comprised between 1 and 12 μιη, each of said first longitudinal incisures (20") having, at its interior, second longitudinal microincisures (20"') having a width of the transverse section comprised between 0.
2- 0.3 μηι, said first longitudinal incisures (20") and said second microincisures defining a system of striated bands, said second longitudinal microincisures (20"') being repeated on each of said surfaces (20') with an axile periodicity of 64-70 nm, said medication kit also being characterized in that each module (20) has, on said surface (20'), pores having a surface area comprised between 20-150 μιη , said medication kit also being characterized in that on each of said surfaces (20'), a film (30) is present, of variable thickness, of a common medicine adapted to treat lesions of the integumentary tissues represented by burns.
Medication kit according to the preceding claim characterized in that the modules (20) comprised in said medication kit are made of materials such as PLA and/or PLGA or of block copolymers such as alginates or of amorphous polymers such as EPR rubbers
3. Medication kit according to any one of the preceding claims characterized in that the medicine of the film (30) present on the surface (20') of each module (20) is an oil/unguent, or an ointment or a foam. 4. Medication kit according to the preceding claim characterized in that the medicine of the film (30) present on the surface (20') of each module (20) is an ointment comprising: 8% to 10% of a decoction based on thyme, elderberry and mallow; 40% to 45% of soybean oil; 23% to 29% of hydrophilic emulsifying emollient with base of C12-C13 alcohol lactate and/or polyglycerols, 0.7% to 1.4% of benzocaine; 0.08% to 0.3% of colloidal sulfur; 2% to 6% of benzyl alcohol; 0.3% to 0.9% of sodium borate; 0.07% to
0.5% of calcium hydrate; 0.07% to 0.5% of calcium iodide; 0.05% to 0.
4% of potassium iodide, 0.01% to 0.05% of thio sulfate.
5. Medication kit according to any one of the preceding claims characterized in that the medicinal film (30) present on the surface (20') of each module (20) is covered with a film of chemically inert material that is if necessary removed.
6. Medication kit according to any one of the preceding claims characterized in that the modules (20) are themselves modulatable, said medication kit comprising a sterile scalpel (40) and a layer of chemically inert and sterile material shaped as a flexible mat
(50), on which it is possible to extend the module (20) that one intends to cut, in order to obtain a particular profile thereof, by means of the use of said sterile scalpel (40).
7. Medication kit according to any one of the preceding claims characterized in that the case-like container (10) is a refrigerator container.
8. Medication kit according to any one of the preceding claims characterized in that the case-like container (10) comprises, at each compartment, at least one indication such as
a label or the like indicating the module (20) type, with the profile of specific anatomic portions of human integuments, contained in the compartment(s), said modules (20) also having indications such as writing, numbers, figures or the like adapted for the recognition thereof, said container (10) also comprising an illustrative key or sheet that shows how to identify and use said modules (20).
Medication kit according to any one of the preceding claims for use in a method for treating lesions of the integumentary tissues.
Medication kit according to any one of the claims from 1 to 8 for use in a method for treating lesions of the integumentary tissues represented by burns.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITUA2016A002781A ITUA20162781A1 (en) | 2016-04-21 | 2016-04-21 | KIT OF MEDICATIONS FOR USE IN THE TREATMENT OF INJURIES OF TEGUMENTARY TISSUES. |
IT102016000041189 | 2016-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017182989A1 true WO2017182989A1 (en) | 2017-10-26 |
Family
ID=56684140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/052295 WO2017182989A1 (en) | 2016-04-21 | 2017-04-21 | Medication kit adapted to treat lesions of the integumentary tissues |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITUA20162781A1 (en) |
WO (1) | WO2017182989A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900006248A1 (en) * | 2019-04-23 | 2020-10-23 | Edelweis Zeppa | COMPOUND FOR THE TREATMENT OF INJURIES AND BURNS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034751A (en) * | 1975-11-24 | 1977-07-12 | International Paper Company | Polymeric sheets as synthetic medical dressings or coverings for wounds |
WO2005065604A1 (en) * | 2004-01-07 | 2005-07-21 | Biopol Co., Ltd. | Wound dressing |
-
2016
- 2016-04-21 IT ITUA2016A002781A patent/ITUA20162781A1/en unknown
-
2017
- 2017-04-21 WO PCT/IB2017/052295 patent/WO2017182989A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034751A (en) * | 1975-11-24 | 1977-07-12 | International Paper Company | Polymeric sheets as synthetic medical dressings or coverings for wounds |
WO2005065604A1 (en) * | 2004-01-07 | 2005-07-21 | Biopol Co., Ltd. | Wound dressing |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900006248A1 (en) * | 2019-04-23 | 2020-10-23 | Edelweis Zeppa | COMPOUND FOR THE TREATMENT OF INJURIES AND BURNS |
Also Published As
Publication number | Publication date |
---|---|
ITUA20162781A1 (en) | 2017-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Patil et al. | Silk fibroin and silk-based biomaterial derivatives for ideal wound dressings | |
Shah et al. | Biopolymer-based biomaterials for accelerated diabetic wound healing: A critical review | |
Moraes et al. | Bacterial cellulose/collagen hydrogel for wound healing | |
Biagini et al. | Wound management with N-carboxybutyl chitosan | |
Thomas | Alginate dressings in surgery and wound management—Part 1 | |
EP2366721B1 (en) | Medical kit for use during negative pressure wound therapy | |
Bielecki et al. | Wound dressings and cosmetic materials from bacterial nanocellulose | |
Sharma et al. | Recent advances of chitosan composites in artificial skin: the next era for potential biomedical application | |
Alizadeh et al. | PDGF and VEGF-releasing bi-layer wound dressing made of sodium tripolyphosphate crosslinked gelatin-sponge layer and a carrageenan nanofiber layer | |
Anniboletti et al. | Clinical activity of innovative non-woven tissues | |
US20230301932A1 (en) | Multilayer composite material | |
Yaşayan et al. | Natural polymers for wound dressing applications | |
Rivero et al. | Nanofibrous scaffolds for skin tissue engineering and wound healing applications | |
Singh et al. | Natural polymer-based thin film strategies for skin regeneration in lieu of regenerative dentistry | |
Pajooh et al. | Biomimetic VEGF-loaded bilayer scaffold fabricated by 3D printing and electrospinning techniques for skin regeneration | |
WO2017182989A1 (en) | Medication kit adapted to treat lesions of the integumentary tissues | |
Bianchi et al. | Gas foamed scaffolds as smart 3D structures in skin tissue engineering | |
Nqoro et al. | Alginate-based wound dressings for skin healing and regeneration | |
KR20150090916A (en) | Histo-equivalent bioplastic material | |
Smirnova et al. | Tissue reconstruction of skin failures and soft-tissue injuries using regenerative medicine methods | |
Tsegay et al. | Smart 3D Printed Hydrogel Skin Wound Bandages: A Review. Polymers 2022, 14, 1012 | |
Rajkumar et al. | Chitosan-Based Biomaterial in Wound Healing: A Review | |
Mourinho | Development and design of scaffolds for skin repair | |
Susrutha et al. | Types of Wound Dressings and Materials used in Mild to Moderately Exuding Wounds: A Review | |
Kordestani | Natural biopolymers: Wound care applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17727700 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17727700 Country of ref document: EP Kind code of ref document: A1 |